1. Home
  2. GCMG vs BWAY Comparison

GCMG vs BWAY Comparison

Compare GCMG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCM Grosvenor Inc.

GCMG

GCM Grosvenor Inc.

HOLD

Current Price

$10.56

Market Cap

686.0M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$15.18

Market Cap

674.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCMG
BWAY
Founded
1971
2003
Country
United States
Israel
Employees
553
129
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
686.0M
674.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GCMG
BWAY
Price
$10.56
$15.18
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$14.33
$13.25
AVG Volume (30 Days)
323.9K
139.3K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
4.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.28
$309.69
Revenue Next Year
$11.70
$26.21
P/E Ratio
$28.21
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$9.30
$10.01
52 Week High
$13.22
$26.63

Technical Indicators

Market Signals
Indicator
GCMG
BWAY
Relative Strength Index (RSI) 45.00 43.04
Support Level $10.35 $14.56
Resistance Level $11.84 $16.63
Average True Range (ATR) 0.41 0.62
MACD -0.09 -0.20
Stochastic Oscillator 20.44 21.03

Price Performance

Historical Comparison
GCMG
BWAY

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: